NCT03301805View on ClinicalTrials.gov

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

BLEX 404

"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."

All Listed Sponsors
collaborator

American BriVision Corporation

UNKNOWN

lead

Rgene Corporation

INDUSTRY